Investigation on alterations of skin-infiltrating T cell populations and peripheral blood biomarkers upon administration of Cosentyx (secukinumab) in patients with plaque psoriasis
Latest Information Update: 20 Aug 2018
At a glance
- Drugs Secukinumab (Primary)
- Indications Plaque psoriasis
- Focus Biomarker; Therapeutic Use
- 09 Aug 2018 Status changed from active, no longer recruiting to completed.
- 01 Feb 2018 Status changed from not yet recruiting to active, no longer recruiting.
- 02 Aug 2016 New trial record